Drug Profile
MRX 2843
Alternative Names: MRX-2843Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Emory University; Meryx; National Cancer Institute (USA)
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Haematological malignancies; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
- 28 May 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO, Capsule)